AMGEN APPOINTS NEW BUSINESS UNIT DIRECTOR OF ONCOLOGY

Cambridge, England, (8 March, 2007) – Amgen has appointed John de Wit as business unit director oncology, for the UK and Ireland.

John, who joined Amgen in 1996, has developed a heritage in oncology and haematology sales and marketing, both at a local and international level. For the past three years John has been an oncology brand director at Amgen’s international headquarters in Switzerland. John holds an MSc in pharmaceutical science from the University of Utrecht.

Commenting on his appointment John de Wit said: “This is a particularly exciting time to join the oncology business unit in the UK. While Amgen’s profile in the oncology world is already well-established, we are optimistic about the future as we have a number of targeted therapeutics in the late stages of development,”

Amgen has been at the forefront of biotechnology for more than 25 years. Its medicines have helped millions of patients with cancer, kidney disease, rheumatoid arthritis and other serious illnesses around the world. The company employs more than 20,000 people globally.

     
For further information, please contact:
Amgen Ltd
Nigel Thornton
Head of Communications
Tel: 01223 436 459

Notes to editors:

About Amgen
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.co.uk/science/science.html.